IV Curcumin Cancer Care

Curcumin, also known as diferuloylmethane, is a yellow pigmented polyphenol which gives turmeric (Curcuma longa), a spice commonly used in India, its yellow color. Curcumin is one of the most well-researched natural agents on the planet. It has been found to provide numerous benefits as an adjunctive anti-cancer agent. Curcumin targets many pathways associated with the development and growth of cancer. Studies have shown that curcumin inhibits cancer cell growth, invasion and metastasis. It also reduces cancer cell blood vessel formation and induces cancer cell death. Studies have also found that curcumin may enhance the effectiveness of conventional oncology therapies and reduce their side effects. Furthermore, curcumin is a potent antioxidant and anti-inflammatory agent and can a useful aid in multiple other conditions.  One of the main issues with curcumin administration is that it is poorly absorbed when taken orally. However, intravenous administered allows for complete absorption of the molecule which provides the greatest therapeutic benefit.

The administration of ALA is safe and well-tolerated in most patients. Side effects are rare, but can include low blood sugar, nausea, vomiting, vertigo, gastric upset and allergic reactions. With any intravenous infusion there is risk of pain and inflammation at the injection site as well as the risk of infiltration (IV fluid leaking outside of the vein).  High doses of ALA have been administered in multiple studies and there have been no documented fatal overdoses or severe reactions to ALA in the literature.

Due to the hypoglycemia effects of ALA caution should be advised in diabetics who are receiving ALA. Diabetics receiving ALA should closely monitor their blood glucose levels. One study found that ALA administration is safe in diabetic patients with hepatic impairment.